Swine Dysentery
Swine Dysentery caused by Brachyspira hyodysenteriae is one of the most expensive diseases of the growing pig. Swine Dysentery is common in pigs from 12 to 75kg weight and occasionally in sows and piglets. The disease has a marked depressant effect on feed conversion and daily gain with symptoms appearing intermittently. Continual exposure to infective faeces is a major factor in the maintenance of disease in herds.
The development of immunity to Swine Dysentery is slow and pigs may succumb to infections a number of times before full immunity is achieved. Current methods to control Swine Dysentery include the use of antibiotics. However, the use of antibiotics is not a sustainable option due to the rapid emergence of antibiotic resistance and increasing regulatory stringency in the livestock industry.
There is an unmet need for alternative therapies to control or prevent Swine Dysentery. A vaccine to prevent Swine Dysentery is an ideal option. Through the research expertise of Professor David Hampson, Spirogene has embarked on an intensive R&D program to develop vaccines against Swine Dysentery.
Cells of Brachyspira hyodysenteriae
Swine dysentery evidenced by bloody diarrhoea
Avian Intestinal Spirochaetosis
Avian Intestional Spirochaetosis (AIS) is an emerging disease of poultry caused by three pathogenic Brachyspira species: Brachyspira intermedia, Brachyspira pilosicoli and Brachyspira alvinipulli. Avian Intestinal Spirochaetosis is a disease affecting commercial and free-range laying hens, resulting in chronic diarrhoea, wet litter and faecal staining of eggs. The wet litter is an industry problem resulting in production losses due to faecal-stained eggs. A 10% reduction in egg laying capacity is also observed.
In the last 10 years, researchers in Europe, the USA and Australia have been able to differentiate between pathogenic and non-pathogenic spirochaetes involved in AIS. Peer-reviewed journal articles revealed that AIS was found in approximately 68% of the laying flocks in Australia and comparable estimates exist in other countries. This previously under-recognised disease is now gaining major research and commercial attention.
There are currently no registered, nor effective treatment and diagnostic options for AIS. Spirogene is working with Professor David Hampson to fulfill an unmet market need for an effective vaccine and innovative diagnostic solution for AIS.
(Top) Frothy and caramel-coloured faecal sample consistent with Avian Intestinal Spirochaetosis
(Bottom) Normal fecal sample
Normal egg (left) compared to faecal-stained, AIS affected egg (right)
Literature Resources
